Loading

Localized Prostate Cancer

AS Plus Enzalutamide Monotherapy Versus AS Alone for Localized Prostate Cancer

In a recently published report in JAMA Oncology, Shore et al evaluated the addition of enzalutamide to the current standard of care for patients with low- or intermediate-risk prostate cancer.1 According to the current National Comprehensive Cancer Network® (NCCN) guidelines, active surveillance (AS) is the current preferred recommendation for patients with very-low-risk and low-risk prostate cancer. For patients with intermediate-risk disease, AS is recommended, but not necessarily preferred over definitive therapy such as surgery or radiation.2 ...

Advertisement

Latest News

Advertisement

Prostate Cancer Knowledge Hubs

Curated clinical content based on prostate cancer types, therapies, and technologies

Prostate Cancer
Prostate Cancer

Conference Coverage

Advertisement
Advertisement
Trending

Patrick Daly

Advanced Urothelial Carcinoma | February 11, 2022

The authors said that “PDEARGs are valuable prognostic predictors and potential therapeutic targets” for patients with ...

Patrick Daly

Advanced Urothelial Carcinoma | March 21, 2022

Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.

Patrick Daly

Advanced Urothelial Carcinoma | March 21, 2022

Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.